FAP and neoplasm: This included a subsequent infusion of CAR-T cells targeting the PDAC tumor-associated antigen mesothelin, resulting in enhanced tumor control.4 Importantly a phase I trial of FAP+ mesotheliomas reported that FAP CAR-T cells administered intrapleurally were well tolerated.5